Table 4

Drug combinations

Drug combinationA549H460SHP77
LowaMediumHighLowMediumHighLowMediumHigh
Exisulindb + sulfide−−c+++++±+++±
      + NDGA−−+++++±±±−−±++
      + 13-cis-RA−−+++++−−±++++−−±+++
      + cisplatin++±±±±±++
      + paclitaxel−−±++−−±+−−−−+++
Sulfide + NDGA     −−±+−−−−+±
     + 13-cis-RA−−+++++++−−+++−−++++
     + cisplatin−−±−−+++++−−±+
     + paclitaxel−−+−−±+++++
NDGA + 13-cis-RA−−++++++−−++++−−+++++++
     + cisplatin−−±±−−±+−−±+
     + paclitaxel±±−−++++−−−−−−
    13-cis-RA + cisplatin+±+±+±+++++
    + paclitaxel±±++++±++++++±++
Cisplatin + paclitaxel±++±−−++±++±
  • a Low, medium, and high indicate drug concentrations with low being 1–2 times lower than the approximate IC050 of the drug, medium at the IC50, and high 1–2 times greater than the approximate IC50.

  • b Exisulind, sulindac sulfone; sulfide [as used in the table], sulindac sulfide; RA, retinoic acid.

  • c Summary of symbols:

    −−       =  CI > 1.3   —  antagonism

    −        =  CI 1.1–1.3 —  moderate antagonism

    ±       =  CI 0.9–1.1 —  additive effect

    +       =  CI 0.8–0.9 —  slight synergism

    ++     =  CI 0.6–0.8 —  moderate synergism

    +++   =  CI 0.4–0.6 —  synergism

    ++++ =  CI 0.2–0.4 —  strong synergism